Larimar Therapeutics Inc (LRMR) Stock Price, Quote & News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 844-511-9056

Website: larimartx.com

Address:

Three Bala Plaza East, Suite 506, Bala Cynwyd, United States

MarkAP Sep. 14 at 2:11 PM

$LRMR Interesting, as per Fidelity, the unconfirmed date for Q3 earnings will be October 28, 2025

0 · Reply

nirahl Sep. 14 at 1:50 AM

$LRMR One of Larimiar's competitors, PTC Therapeutics, received a CRL for their drug vatiquinone (15-Lipoxygenase Inhibitor) in phase 3 trial on 8/19/25. More market share for LRMR.

1 · Reply

Buss Sep. 12 at 9:22 PM

$LRMR Curious AH activity...something brewing & afoot?

1 · Reply

dbr_island Sep. 12 at 9:19 PM

$PLRZ everyone thought I was delusional when I said CCXI would hit $50 from under $10 NOT only did I call this from under $10 to $50 ✅ I ACTUALLY BUY👇🚢📦📦📦📦📦📦📦📦📦 Now I’m laughing ALL the way to the 🏦✅ PLRZ is my next BIG pay day ‼️🚨‼️🚨‼️ WATCH AND LEARN $CHEK $RETO $LRMR $INTJ let’s get it

0 · Reply

judgeyoung2 Sep. 12 at 7:38 PM

$LRMR did they actually say sept 22 specifically for the data?

1 · Reply

Dani_G_German Sep. 12 at 7:09 PM

$LRMR nice bounce Lfg!!

0 · Reply

Chartist0_0 Sep. 12 at 5:41 PM

$LRMR 3.25 to 3.50$ incoming

2 · Reply

elmono Sep. 12 at 5:17 PM

$KURA $LRMR giving up a weeks gain like it was nothing…still a turd sector.

0 · Reply

hbkstockislife Sep. 12 at 5:00 PM

$LRMR one of the worst stocks in this bull market when you money can be stuck ..be careful ..all up 100-200% past month and this one lol

1 · Reply

MarkAP Sep. 12 at 4:54 PM

$LRMR oh lord, I hope they release the results sooner

0 · Reply

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 4:15 PM EDT - 6 weeks ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 29, 2025, 11:50 PM EDT - 6 weeks ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Jul 29, 2025, 4:01 PM EDT - 6 weeks ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Jul 8, 2025, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 20, 2025, 4:05 PM EDT - 3 months ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 6 months ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 6 months ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Jan 23, 2025, 4:05 PM EST - 8 months ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Jan 3, 2025, 5:49 PM EST - 9 months ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Dec 17, 2024, 1:39 PM EST - 9 months ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 16, 2024, 12:17 PM EST - 9 months ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 7:00 AM EST - 9 months ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Oct 30, 2024, 7:00 AM EDT - 11 months ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 16, 2024, 2:59 PM EDT - 11 months ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oct 6, 2024, 9:28 PM EDT - 1 year ago

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

May 31, 2024, 4:11 PM EDT - 1 year ago

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 30, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 9, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 6, 2024, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 14, 2024, 6:15 AM EST - 1 year ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 12, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Nov 14, 2023, 7:00 AM EST - 1 year ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Oct 3, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 2, 2023, 6:02 AM EDT - 2 years ago

Larimar: Friedreich's Ataxia Drug With Significant Potential

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jun 21, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

May 15, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

Mar 28, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

Feb 7, 2023, 4:05 PM EST - 2 years ago

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

Nov 21, 2022, 4:05 PM EST - 3 years ago

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

Nov 10, 2022, 7:00 AM EST - 3 years ago

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

Nov 7, 2022, 4:05 PM EST - 3 years ago

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

Oct 19, 2022, 4:05 PM EDT - 3 years ago

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

Sep 26, 2022, 9:59 AM EDT - 3 years ago

MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An Edge

AAPL AMGN CAT CELH CLFD CVX DOW

Sep 16, 2022, 1:00 PM EDT - 3 years ago

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

Sep 14, 2022, 7:04 AM EDT - 3 years ago

Larimar Therapeutics Announces $70 Million Underwritten Offering

Sep 14, 2022, 7:01 AM EDT - 3 years ago

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia Patients

MarkAP Sep. 14 at 2:11 PM

$LRMR Interesting, as per Fidelity, the unconfirmed date for Q3 earnings will be October 28, 2025

0 · Reply

nirahl Sep. 14 at 1:50 AM

$LRMR One of Larimiar's competitors, PTC Therapeutics, received a CRL for their drug vatiquinone (15-Lipoxygenase Inhibitor) in phase 3 trial on 8/19/25. More market share for LRMR.

1 · Reply

Buss Sep. 12 at 9:22 PM

$LRMR Curious AH activity...something brewing & afoot?

1 · Reply

dbr_island Sep. 12 at 9:19 PM

0 · Reply

judgeyoung2 Sep. 12 at 7:38 PM

$LRMR did they actually say sept 22 specifically for the data?

1 · Reply

Dani_G_German Sep. 12 at 7:09 PM

$LRMR nice bounce Lfg!!

0 · Reply

Chartist0_0 Sep. 12 at 5:41 PM

$LRMR 3.25 to 3.50$ incoming

2 · Reply

elmono Sep. 12 at 5:17 PM

$KURA $LRMR giving up a weeks gain like it was nothing…still a turd sector.

0 · Reply

hbkstockislife Sep. 12 at 5:00 PM

$LRMR one of the worst stocks in this bull market when you money can be stuck ..be careful ..all up 100-200% past month and this one lol

1 · Reply

MarkAP Sep. 12 at 4:54 PM

$LRMR oh lord, I hope they release the results sooner

0 · Reply

Dani_G_German Sep. 12 at 4:40 PM

$LRMR I thought closing above 4 for two consecutive days was gonna be the start of something new but I guess not. Still holding though.

0 · Reply

elmono Sep. 12 at 3:56 PM

$KURA $LRMR $XBI choppy Friday in biotech country 🤷‍♂️

0 · Reply

elmono Sep. 12 at 11:26 AM

$LRMR tightly controlled turd. Not allowed to rise

1 · Reply

Xanderzzzzzzz Sep. 12 at 10:38 AM

$LRMR https://beyondspx.com/quote/LRMR/analysis/larimar-therapeutics-unlocking-frataxin-and-the-race-for-accelerated-approval-in-friedreich-s-ataxia-nasdaq-lrmr

0 · Reply

MarkAP Sep. 11 at 7:39 PM

$LRMR when will they release data?

2 · Reply